CL2018003573A1 - Anti-c5 antibodies and methods of use. - Google Patents
Anti-c5 antibodies and methods of use.Info
- Publication number
- CL2018003573A1 CL2018003573A1 CL2018003573A CL2018003573A CL2018003573A1 CL 2018003573 A1 CL2018003573 A1 CL 2018003573A1 CL 2018003573 A CL2018003573 A CL 2018003573A CL 2018003573 A CL2018003573 A CL 2018003573A CL 2018003573 A1 CL2018003573 A1 CL 2018003573A1
- Authority
- CL
- Chile
- Prior art keywords
- antibody
- present
- provides
- antibodies
- methods
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 2
- 239000002253 acid Substances 0.000 abstract 3
- 238000004519 manufacturing process Methods 0.000 abstract 2
- 150000007513 acids Chemical class 0.000 abstract 1
- 230000003053 immunization Effects 0.000 abstract 1
- 229940126601 medicinal product Drugs 0.000 abstract 1
- 230000007935 neutral effect Effects 0.000 abstract 1
- 229920001184 polypeptide Polymers 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
LA INVENCIÓN SE REFIERE A ANTICUERPOS ANTI-C5 Y MÉTODOS PARA USARSE. EN ALGUNAS MODALIDADES, UN ANTICUERPO ANTI-C5 AISLADO DE LA PRESENTE INVENCIÓN SE UNE A UN EPÍTOPO DENTRO DE LA CADENA BETA DE C5 CON MAYOR AFINIDAD A UN PH NEUTRO QUE A UN PH ÁCIDO. LA INVENCIÓN TAMBIÉN PROPORCIONA ÁCIDOS NUCLÉICOS AISLADOS QUE CODIFICAN UN ANTICUERPO ANTI-C5 DE LA PRESENTE INVENCIÓN. LA INVENCIÓN TAMBIÉN PROPORCIONA CÉLULAS HOSPEDERAS QUE COMPRENDEN UN ÁCIDO NUCLÉICO DE LA PRESENTE INVENCIÓN. LA INVENCIÓN TAMBIÉN PROPORCIONA UN MÉTODO PARA PRODUCIR UN ANTICUERPO QUE COMPRENDE CULTIVAR UNA CÉLULA HOSPEDERA DE LA PRESENTE INVENCIÓN A FIN DE PRODUCIR EL ANTICUERPO. LA INVENCIÓN PROPORCIONA ADEMÁS UN MÉTODO PARA PRODUCIR UN ANTICUERPO ANTI-C5 QUE COMPRENDE INMUNIZAR UN ANIMAL CONTRA UN POLIPÉPTIDO QUE COMPRENDE EL DOMINIO MG1-MG2 DE LA CADENA BETA DE C5. LOS ANTICUERPOS ANTI-C5 DE LA PRESENTE INVENCIÓN SE PUEDEN USAR COMO MEDICAMENTO.THE INVENTION REFERS TO ANTI-C5 ANTIBODIES AND METHODS FOR USE. IN SOME MODES, AN ANTI-C5 ANTIBODY ISOLATED FROM THE PRESENT INVENTION JOINS AN EPITHOPE WITHIN THE BETA CHAIN OF C5 WITH GREATER AFFINITY TO A NEUTRAL PH THAN AN ACID PH. THE INVENTION ALSO PROVIDES ISOLATED NUCLETIC ACIDS THAT CODIFY AN ANTI-C5 ANTIBODY OF THE PRESENT INVENTION. THE INVENTION ALSO PROVIDES HOSPED CELLS THAT INCLUDE A NUCLETIC ACID OF THE PRESENT INVENTION. THE INVENTION ALSO PROVIDES A METHOD FOR PRODUCING AN ANTIBODY THAT INCLUDES CULTIVATING A HOSPED CELL OF THIS INVENTION TO PRODUCE THE ANTIBODY. THE INVENTION ALSO PROVIDES A METHOD FOR PRODUCING AN ANTI-C5 ANTIBODY THAT INCLUDES IMMUNIZING AN ANIMAL AGAINST A POLYPEPTIDE THAT INCLUDES DOMAIN MG1-MG2 OF THE BETA CHAIN OF C5. THE ANTI-C5 ANTIBODIES OF THE PRESENT INVENTION CAN BE USED AS A MEDICINAL PRODUCT.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2016120325 | 2016-06-17 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2018003573A1 true CL2018003573A1 (en) | 2019-02-01 |
Family
ID=59969459
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2018003573A CL2018003573A1 (en) | 2016-06-17 | 2018-12-12 | Anti-c5 antibodies and methods of use. |
Country Status (19)
| Country | Link |
|---|---|
| EP (1) | EP3472316A4 (en) |
| JP (4) | JP6202774B1 (en) |
| KR (2) | KR101852739B1 (en) |
| CN (3) | CN115960223A (en) |
| AU (1) | AU2017285763B2 (en) |
| BR (1) | BR112018075688A2 (en) |
| CA (1) | CA3021956A1 (en) |
| CL (1) | CL2018003573A1 (en) |
| CR (1) | CR20190013A (en) |
| EA (1) | EA201990018A1 (en) |
| IL (2) | IL300611A (en) |
| MX (2) | MX2018015030A (en) |
| MY (1) | MY187848A (en) |
| PE (2) | PE20240825A1 (en) |
| PH (1) | PH12018502354A1 (en) |
| SG (2) | SG11201705584VA (en) |
| TW (4) | TWI807666B (en) |
| UA (1) | UA126561C2 (en) |
| WO (1) | WO2017217524A1 (en) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK3056568T3 (en) | 2006-03-31 | 2021-11-01 | Chugai Pharmaceutical Co Ltd | PROCEDURES FOR CONTROL OF THE BLOOD PHARMACOKINETICS OF ANTIBODIES |
| JP5334319B2 (en) | 2007-09-26 | 2013-11-06 | 中外製薬株式会社 | Method for modifying isoelectric point of antibody by amino acid substitution of CDR |
| EP3521311A1 (en) | 2008-04-11 | 2019-08-07 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly |
| RU2642318C2 (en) | 2010-11-30 | 2018-01-24 | Чугаи Сейяку Кабусики Кайся | Antigen-binding molecule, able to multiplely contact with plurality of antigenic molecules |
| LT3233921T (en) | 2014-12-19 | 2021-12-10 | Chugai Seiyaku Kabushiki Kaisha | Anti-c5 antibodies and methods of use |
| KR20240070728A (en) | 2016-06-14 | 2024-05-21 | 리제너론 파아마슈티컬스, 인크. | Anti-c5 antibodies and uses thereof |
| BR112018075688A2 (en) * | 2016-06-17 | 2019-04-02 | Chugai Seiyaku Kabushiki Kaisha | anti-c5 antibodies and methods of use |
| TWI693940B (en) | 2016-08-05 | 2020-05-21 | 日商中外製藥股份有限公司 | Composition for the treatment or prevention of IL-8 related diseases |
| JP2020536097A (en) * | 2017-10-04 | 2020-12-10 | アレクシオン ファーマシューティカルズ， インコーポレイテッド | Dosage and administration of anti-C5 antibody for the treatment of patients with membranous proliferative glomerulonephritis |
| WO2019118556A1 (en) | 2017-12-13 | 2019-06-20 | Regeneron Pharmaceuticals, Inc. | Anti-c5 antibody combinations and uses thereof |
| BR112021004141A2 (en) * | 2018-09-06 | 2021-05-25 | The Trustees Of The University Of Pennsylvania | ph-dependent antibody that specifically binds to human c5, methods of treating a complement pathway mediated disease or disorder in an individual and of reducing the activity of a genetically modified individual, cell, and non-human animal complement system. |
| CN114072174A (en) * | 2019-04-24 | 2022-02-18 | 宾夕法尼亚大学理事会 | Dual-function humanized anti-C5 antibody and factor H fusion protein and uses thereof |
| CN113563467A (en) * | 2020-04-28 | 2021-10-29 | 上海普铭生物科技有限公司 | Antibodies against human complement protein C5 and uses thereof |
| EP4181958A4 (en) | 2020-07-15 | 2024-03-06 | Biosion, Inc. | Antibodies binding c5 and uses thereof |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0230985Y2 (en) | 1985-07-08 | 1990-08-21 | ||
| US6074642A (en) | 1994-05-02 | 2000-06-13 | Alexion Pharmaceuticals, Inc. | Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis |
| DE60143859D1 (en) | 2001-06-12 | 2011-02-24 | Ericsson Telefon Ab L M | SYNCHRONIZATION IN A TERRESTRIAL UMTS RADIO ACCESS NETWORK (UTRAN) |
| ATE360441T1 (en) | 2001-08-17 | 2007-05-15 | Tanox Inc | COMPLEMENT INHIBITORS THAT BIND TO C5 AND C5A WITHOUT INHIBITING THE FORMATION OF C5B |
| JP4333939B2 (en) | 2001-08-27 | 2009-09-16 | ロード・コーポレーション | Trolley wire suspension system |
| DE10253331A1 (en) | 2002-11-14 | 2004-06-03 | Symrise Gmbh & Co. Kg | Use of trans-pellitori as a flavoring |
| US7267849B2 (en) | 2004-03-02 | 2007-09-11 | Nitto Denko Corporation | Compensator for liquid crystal display |
| KR20080069889A (en) | 2007-03-20 | 2008-07-29 | (주)화도 | Pe pipe |
| CN101679486A (en) * | 2007-03-22 | 2010-03-24 | 诺瓦提斯公司 | c5 antigens and uses thereof |
| JP5336846B2 (en) | 2007-04-11 | 2013-11-06 | 積水化学工業株式会社 | Method for producing crosslinked polyvinyl acetal resin and crosslinked polyvinyl acetal resin |
| EP3521311A1 (en) * | 2008-04-11 | 2019-08-07 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly |
| AR072897A1 (en) * | 2008-08-05 | 2010-09-29 | Novartis Ag | COMPOSITIONS AND METHODS FOR ANTIBODIES GOING TO COMPLEMENT PROTEIN C5 |
| KR20100054403A (en) | 2008-11-14 | 2010-05-25 | 삼성전자주식회사 | Online composition apparatus and method for writing by multiple participants |
| CN105218674A (en) * | 2010-03-11 | 2016-01-06 | 瑞纳神经科学公司 | The antibody combined in pH dependence antigen |
| TW201206466A (en) * | 2010-03-11 | 2012-02-16 | Rinat Neuroscience Corp | Antibodies with pH dependent antigen binding |
| KR20110111007A (en) | 2010-04-02 | 2011-10-10 | 이화여자대학교 산학협력단 | Octahydro-binaphthol derivatives for l/d optical conversion and optical resolution |
| KR20110122011A (en) | 2010-05-03 | 2011-11-09 | 황보철종 | System for administrating combine store point and method therefor |
| JP6309521B2 (en) * | 2012-08-13 | 2018-04-11 | リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | Anti-PCSK9 antibody with pH-dependent binding properties |
| US10280215B2 (en) * | 2013-01-31 | 2019-05-07 | Seoul National University R&Db Foundation | Anti-C5 antibodies and methods of treating complement-related diseases |
| WO2014160958A1 (en) * | 2013-03-29 | 2014-10-02 | Alexion Pharmaceuticals, Inc. | Compositions and methods for increasing the serum half-life of a therapeutic agent targeting complement c5 |
| NZ711451A (en) * | 2014-03-07 | 2016-05-27 | Alexion Pharma Inc | Anti-c5 antibodies having improved pharmacokinetics |
| LT3233921T (en) * | 2014-12-19 | 2021-12-10 | Chugai Seiyaku Kabushiki Kaisha | Anti-c5 antibodies and methods of use |
| EA036756B1 (en) * | 2015-12-18 | 2020-12-16 | Чугаи Сейяку Кабусики Кайся | Anti-c5 antibodies and methods of use thereof |
| BR112018075688A2 (en) * | 2016-06-17 | 2019-04-02 | Chugai Seiyaku Kabushiki Kaisha | anti-c5 antibodies and methods of use |
-
2017
- 2017-06-16 BR BR112018075688-1A patent/BR112018075688A2/en unknown
- 2017-06-16 JP JP2017118226A patent/JP6202774B1/en active Active
- 2017-06-16 MY MYPI2018002581A patent/MY187848A/en unknown
- 2017-06-16 PE PE2023002969A patent/PE20240825A1/en unknown
- 2017-06-16 WO PCT/JP2017/022253 patent/WO2017217524A1/en active Application Filing
- 2017-06-16 EP EP17813418.5A patent/EP3472316A4/en active Pending
- 2017-06-16 SG SG11201705584VA patent/SG11201705584VA/en unknown
- 2017-06-16 SG SG10201800265UA patent/SG10201800265UA/en unknown
- 2017-06-16 TW TW111107923A patent/TWI807666B/en active
- 2017-06-16 CN CN202211018018.5A patent/CN115960223A/en active Pending
- 2017-06-16 AU AU2017285763A patent/AU2017285763B2/en active Active
- 2017-06-16 MX MX2018015030A patent/MX2018015030A/en unknown
- 2017-06-16 EA EA201990018A patent/EA201990018A1/en unknown
- 2017-06-16 TW TW112120479A patent/TW202337903A/en unknown
- 2017-06-16 TW TW106141573A patent/TWI789369B/en active
- 2017-06-16 KR KR1020177020545A patent/KR101852739B1/en active IP Right Grant
- 2017-06-16 TW TW106120143A patent/TWI610941B/en active
- 2017-06-16 UA UAA201810992A patent/UA126561C2/en unknown
- 2017-06-16 KR KR1020187010179A patent/KR102226975B1/en active IP Right Grant
- 2017-06-16 CR CR20190013A patent/CR20190013A/en unknown
- 2017-06-16 PE PE2018003148A patent/PE20190394A1/en unknown
- 2017-06-16 CA CA3021956A patent/CA3021956A1/en active Pending
- 2017-06-16 CN CN201780036916.4A patent/CN109312326B/en active Active
- 2017-06-16 CN CN202211023851.9A patent/CN115925922A/en active Pending
- 2017-06-16 IL IL300611A patent/IL300611A/en unknown
- 2017-08-28 JP JP2017162934A patent/JP7032077B2/en active Active
-
2018
- 2018-11-08 PH PH12018502354A patent/PH12018502354A1/en unknown
- 2018-12-04 MX MX2023001360A patent/MX2023001360A/en unknown
- 2018-12-12 CL CL2018003573A patent/CL2018003573A1/en unknown
- 2018-12-12 IL IL263657A patent/IL263657A/en unknown
-
2022
- 2022-02-24 JP JP2022026406A patent/JP2022091748A/en active Pending
-
2024
- 2024-04-30 JP JP2024073302A patent/JP2024102181A/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2018003573A1 (en) | Anti-c5 antibodies and methods of use. | |
| CL2018001577A1 (en) | Anti-c5 antibodies and methods of use | |
| CO2017006651A2 (en) | Anti-c5 antibodies | |
| CO2017000510A2 (en) | Car constructs | |
| DOP2018000259A (en) | BISPECIFIC UNION PROTEINS THAT JOIN AN IMMUNOMODULATORY PROTEIN AND A TUMORAL ANTIGEN | |
| NI201700001A (en) | CARRIER-ANTIBODY COMPOSITIONS AND METHODS TO MAKE THEM AND USE THEM | |
| CO2017001573A2 (en) | Chimeric anti-cd123 antigen receptor | |
| UY35468A (en) | CANCER TREATMENT USING AN ANTI-CD19 CHEMERIC ANTIGEN RECEIVER | |
| CL2017002241A1 (en) | Method of cancer treatment associated with a ras mutation | |
| CR20180525A (en) | RIBONUCLEIC ACID PRODUCTION FREE OF CELLS | |
| PE20210107A1 (en) | ANTI-CD3 ANTIBODIES AND METHODS OF USE | |
| EA201592269A1 (en) | METHODS AND COMPOSITIONS FOR REDUCING IMMUNOSUPRESSION BY TUMOR CELLS | |
| AR101845A1 (en) | ANTI-HER2 AND IMMUNOCUSED ANTIBODIES | |
| GB201122047D0 (en) | Transgenic animals | |
| AR090973A1 (en) | USEFUL ANTIBODIES FOR CANCER DIAGNOSIS | |
| AR113490A1 (en) | RNAi CONSTRUCTIONS TO INHIBIT THE EXPRESSION OF PNPLA3 AND METHODS OF USE OF THE SAME | |
| AR091228A1 (en) | METHOD FOR PRODUCING AN IMPROVED VEGETABLE BODY STABILY STABLE WITH AN ENDOFITO | |
| MX2019000641A (en) | Chimeric antigen receptors (cars) specific for muc1 and methods for their use. | |
| MX2023009421A (en) | Dna antibody constructs and method of using same. | |
| MX2017012399A (en) | Anti-cd303 monoclonal antibodies. | |
| PE20211225A1 (en) | ARNI CONSTRUCTS TO INHIBIT THE EXPRESSION OF PNPLA3 | |
| CO2020005371A2 (en) | Anti-apoc3 antibodies and methods of using them | |
| CO2017012397A2 (en) | Fragment of human anti-ngf fab antibody | |
| AR101592A1 (en) | CANCER TREATMENT USING A CHEMERIC ANCIENT RECEIVER CD123 |